The Covid-19 vaccine made by Chinese firm Sinopharm’s Wuhan subsidiary has a 72.5 per cent efficacy rate, the company said on Wednesday. The announcement by the Wuhan Institute of Biological Products came after months of phase 3 clinical trials in several countries around the world. It was the first time the company had published such data, though it did not elaborate on the bare figures. Also on Wednesday, Chinese firm CanSino said interim analysis of the results of its final-stage vaccine trials showed it to have an efficacy rate of more than 65 per cent. Both companies are now hoping to have their vaccines approved for general use in China, having filed applications this week to the National Medical Products Administration. Products made by Sinopharm’s Beijing unit and Sinovac Biotech have already been given the green light for general use in China, while Tianjin-based CanSino’s vaccine has been approved for emergency use in several other countries, including Mexico and Pakistan. China says stockpiling of Covid-19 vaccines by rich countries needs to stop SinoVac’s vaccine was approved for general use in China this month. It was earlier found to be 50.6 per cent effective in preventing Covid-19 in a trial involving health care workers in Brazil, but 91 per cent effective in a much smaller trial conducted in Turkey. State-owned Sinopharm is looking to become the first company to have two Covid-19 vaccines approved, after its first was given the green light in December. CanSino, which jointly developed a vaccine for Ebola, said on Wednesday that as well as the 65 per cent efficacy rate at preventing people getting Covid-19, its new product was 90 per cent effective at protecting against severe symptoms of the disease. The vaccine was developed in cooperation with the Academy of Military Medical Sciences, an institute run by the People’s Liberation Army . PLA General Chen Wei, who was one of four people honoured last year by Chinese President Xi Jinping for their outstanding contributions to the country’s Covid-19 response, began testing the CanSino vaccine on healthy volunteers in Wuhan in March. Despite the progress made by Chinese firms in the development of Covid-19 vaccines, some foreign leaders have questioned their transparency. Earlier this month, French President Emmanuel Macron said there was “absolutely no information” about Chinese vaccines and that they were not as reliable as their Western counterparts. Meanwhile, Europe is one of several regions around the world struggling with vaccine supply. Hungary, which is a member of the European Union bought Chinese vaccines after British-Swedish firm AstraZeneca said last month that deliveries of its product to the bloc would be delayed because of production shortfalls. Beijing has yet to approve any vaccines made by non-Chinese companies for use within its borders.